The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
18:24 10-Mar-2015 AZN Filing of Form 20-F with SEC RNS +0.58% Up
11:00 10-Mar-2015 AZN Annual Financial Report RNS +0.58% Up
07:00 06-Mar-2015 AZN ASTRAZENECA REFINES ITS FINANCIAL REPORTING RNS -2.04% Down
11:54 04-Mar-2015 AZN AZ TO PARTICIPATE IN US FDA EMDAC RNS -1.72% Down
07:05 03-Mar-2015 AZN Acquisition of Rights to Actavis' Portfolio RNS -1.34% Down
15:00 02-Mar-2015 AZN Total Voting Rights RNS -0.86% Down
07:00 17-Feb-2015 AZN Directorate Change RNS -0.63% Down
07:00 16-Feb-2015 AZN PULMICORT RESPULES® US PATENT LITIGATION DECISION RNS -0.68% Down
07:02 05-Feb-2015 AZN AZ to acquire Actavis' US respiratory portfolio RNS -4.57% Down
07:00 05-Feb-2015 AZN Final Results RNS -4.57% Down
09:00 04-Feb-2015 AZN Notice of Results RNS -3.96% Down
14:00 02-Feb-2015 AZN Total Voting Rights RNS -2.81% Down
07:00 22-Jan-2015 AZN MAA FOR GOUT TREATMENT LESINURAD ACCEPTED BY EMA RNS +0.01% Up
07:43 14-Jan-2015 AZN BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT RNS +2.29% Up
14:00 02-Jan-2015 AZN Total Voting Rights RNS -0.24% Down
17:40 19-Dec-2014 AZN LYNPARZA APPROVED BY THE US FDA RNS +1.17% Up
07:00 18-Dec-2014 AZN LYNPARZAT APPROVED IN THE EUROPEAN UNION RNS +0.71% Up
07:00 09-Dec-2014 AZN MOVENTIG approved in the EU for OIC RNS -2.28% Down
17:03 05-Dec-2014 AZN Jury verdict favours AZ in Nexium litigation RNS -0.76% Down
07:00 02-Dec-2014 AZN New Drug Application for IRESSA accepted by US FDA RNS -0.23% Down

 Page 3 of 5

Previous | 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.


Company Information
Updated Monthly
Company address 2 Kingdom Street, London, W2 6BD, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 51,992.28
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market MAINMARKET
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
01-Sep-15
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share - news analysis